Teva Pharmaceutical Industries Ltd (TEVA) Shares Bought by LPL Financial LLC

Saturday, June 30 2018

Teva Pharmaceutical Industries Ltd (TEVA) Shares Bought by LPL Financial LLC

Posted by Craig McOrleans on Jun 30th, 2018 // No Comments
LPL Financial LLC increased its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 9.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 169,319 shares of the company’s stock after buying an additional 15,154 shares during the period. LPL Financial LLC’s holdings in Teva Pharmaceutical Industries were worth $2,894,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in TEVA. Natixis lifted its holdings in shares of Teva Pharmaceutical Industries by 442.6% in the first quarter. Natixis now owns 252,115 shares of the company’s stock valued at $4,309,000 after purchasing an additional 205,655 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $6,092,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the first quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 289,105 shares of the company’s stock valued at $4,941,000 after purchasing an additional 62,000 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at about $264,000. Finally, Baird Financial Group Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 37.0% in the first quarter. Baird Financial Group Inc. now owns 35,893 shares of the company’s stock valued at $613,000 after purchasing an additional 9,689 shares in the last quarter. 65.01% of the stock is currently owned by hedge funds and other institutional investors. Get Teva Pharmaceutical Industries alerts:
In related news, Director Roberto Mignone purchased 750,000 shares of the company’s stock in a transaction that occurred on Thursday, May 10th. The stock was purchased at an average price of $19.24 per share, with a total value of $14,430,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Corporate insiders own 0.43% of the company’s stock. Shares of Teva Pharmaceutical Industries opened at $24.32 on Friday, Marketbeat Ratings reports. Teva Pharmaceutical Industries Ltd has a one year low of $10.85 and a one year high of $33.82. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80. The company has a market cap of $24.04 billion, a P/E ratio of 6.19, a P/E/G ratio of 2.30 and a beta of 0.72.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.63 by $0.28. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.80 billion. During the same quarter in the prior year, the business posted $1.06 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 10.0% compared to the same quarter last year. research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.57 EPS for the current year.
TEVA has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a “hold” rating and issued a $16.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, March 26th. Jefferies Financial Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, March 20th. They issued a “hold” rating and a $19.00 price objective for the company. ValuEngine raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 2nd. Vetr lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating and set a $14.71 price objective for the company. in a research report on Monday, March 26th. Finally, Citigroup set a $25.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Thursday, May 31st. Nine investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.08.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Receive News & Ratings for Teva Pharmaceutical Industries analysts' ratings for Teva Pharmaceutical Industries and related companies daily email newsletter .